SpeeDx announces investment in SynGenis

SpeeDx announced investment in SynGenis Pty Ltd., an experienced oligonucleotide manufacturer based in Western Australia.  The partnership will bolster internal capacity of SpeeDx to support large-scale increases in manufacturing while developing and expanding sovereign capacity of important raw materials used in molecular diagnostics.  SpeeDx investment in local oligonucleotide manufacturing reduces supply chain risk and develops stronger sovereign capacity for critical diagnostics for a more robust national health infrastructure.